- Home
- /
- News
- /
- Drug Trials
- /
- October 2013
Drug Trials News for October 2013
e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder. The trial is evaluating ETS6103 as a second-line treatment for patients who have not responded adequately to first-line therapy with an SSRI (selective serotonin reuptake inhibitor). It is being conducted by a group of primary care centres with a history of involvement in depression studies in the Glasgow area of Scotland.
31 October, 2013
Hundreds of researchers from North America, Europe, Australia and Asia have joined together in a consortium to identify the genetic basis of the five most common forms of cancer - breast, prostate, lung, ovarian and colorectal. The group, called the OncoArray Consortium, developed a new customized genotyping tool - the OncoArray - manufactured by the U.S. genomics firm Illumina, Inc.
10 October, 2013
Korea is to develop its first national centre of excellence for the development and validation of alternatives to animal testing. Humane Society International, which works with governments and scientists in Korea and globally to replace animals in research, says this will dramatically improve Korea's ability to implement cutting-edge science.
08 October, 2013